
    
      Thalidomide:

      First part of the trial: 82 patients at 200mg/day given at bedtime x 12 weeks, decreased to
      100mg/day if grade 1 or 2 side. Stopped temporally for 1 week if grade 3 or 4 side effects.
      Then reintroduced at the same dose. If side effects again, definitively stopped.

      Responses evaluated at 12 weeks according to IWG criteria for the erythroid lineage

      At week 12:

        -  If no Hematological improvement (HI): increased to 300mg/day for 8 weeks and then
           eventually to 400mg/day for 8 weeks more, if no HI.

        -  If Hematological improvement (HI): continued at the same dose.

      Second part of the trial: 30 patients treated at 50mg/day x 12 weeks. Responses evaluated at
      12 weeks according to IWG criteria for the erythroid lineage

      At week 12:

        -  If no Hematological improvement (HI): increased to 100mg/day for 8 weeks and then
           eventually to 200mg/day for 8 weeks more, if no HI.

        -  If Hematological improvement (HI): continued at the same dose.
    
  